SCHEMBL19084684

SCHEMBL19084684

Cc1nn2c(=O)cc(-c3ccc([N+](=O)[O-])cc3)[nH]c2c1-c1cccc(Cl)c1Cl

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSD A5PKW4 8/20 0.53
ADORA2A P29274 1/20 0.38
ADORA1 P30542 1/20 0.38
MAPT P10636 7/20 0.38
CRHBP P24387 1/20 0.38
CRHR2 Q13324 1/20 0.38
ARF6 P62330 2/20 0.37
CCR6 P51684 1/20 0.37
RAB9A P51151 3/20 0.36
ALDH1A1 P00352 3/20 0.36
NPC1 O15118 2/20 0.36
NFKB1 P19838 1/20 0.36
NFKB2 Q00653 1/20 0.36
RELA Q04206 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
MEN1 O00255 4/20 0.36
KMT2A Q03164 4/20 0.36
LMNA P02545 3/20 0.36
HTT P42858 3/20 0.36
CYP1A2 P05177 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13516359 0.86 PSD (0.48) PSDADORA2AADORA1MAPTARF6
SCHEMBL10276296 0.85 PSD (0.52) PSDADORA2AADORA1MAPTARF6
SCHEMBL19084584 0.85 PSD (0.54) PSDADORA2AADORA1MAPTCRHBP
SCHEMBL19084536 0.84 PSD (0.48) PSDADORA2AADORA1MAPTCRHBP
SCHEMBL19084608 0.84 PSD (0.48) PSDADORA2AADORA1MAPTARF6
SCHEMBL17298696 0.84 MAPT (0.41) PSDADORA2AADORA1MAPTCRHBP
SCHEMBL19084599 0.82 PSD (0.52) PSDADORA2AADORA1MAPTCRHBP
SCHEMBL19084648 0.81 PSD (0.53) PSDADORA2AADORA1MAPTARF6
SCHEMBL19084553 0.80 MAPT (0.54) PSDADORA2AADORA1MAPTRAB9A
SCHEMBL19084664 0.80 PSD (0.51) PSDADORA2AADORA1MAPTCCR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10849901-B2 Arf6 inhibitors and methods of synthesis and use thereof NAVIGEN, INC. (US) 2020-12-01 US disclosed
US-20170189405-A1 ARF6 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF NAVIGEN, INC. (US) 2017-07-06 US disclosed
US-20170189405-A1 ARF6 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF NAVIGEN, INC. (US) 2017-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170189405-A1 ARF6 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF ARF6, ARF1, ARFIP2 PSD 211/4885ADORA2A 4263/4885ADORA1 4220/4885
US-10849901-B2 Arf6 inhibitors and methods of synthesis and use thereof ARF6, ARF1, ARFIP2 PSD 211/4885ADORA2A 4263/4885ADORA1 4220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.